Effect of isosorbide through intravaginal administration on the clinical pregnancy rate of cryopreserved embryo transfer in patients with elevated blood flow resistance in uterine arteries

开始日期2019-07-01

申办/合作机构

上海交通大学医学院附属瑞金医院

NCT02718846 / Completed临床4期

A Multicenter, Randomized, Open-label Clinical Study With a Concurrent Control Group to Assess the Effectiveness and Safety of Combined Therapy With Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets for Patients With Meniere's Disease

A multicenter, randomized, open-label clinical study with a concurrent control group to assess the effectiveness and safety of combined therapy with Isobide solution and Meniace tablets compared to monotherapy with Meniace tablets for patients with Meniere's disease

开始日期2013-02-01

申办/合作机构

Alvogen Korea Co., Ltd.

NCT00685945 / CompletedN/AIIT

Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3

The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.

开始日期2007-12-01

申办/合作机构

Vanderbilt University

[+3]

100 项与异山梨醇相关的临床结果

登录后查看更多信息

100 项与异山梨醇相关的转化医学

登录后查看更多信息

100 项与异山梨醇相关的专利（医药）

登录后查看更多信息

286

项与异山梨醇相关的文献（医药）

2024-10-01·Journal of Cosmetic Dermatology

Evaluation of the safety and efficacy of skin penetration enhancer Putocrin®

Article

作者: Chen, Xueping ; Chen, Zhiyuan ; Wang, Ding ; Cen, Zongxiao ; Chen, Junyuan

AbstractBackgroundSubstances that can efficiently enhance skin penetration while exerting no adverse effect are useful for drug and cosmetics formulation.ObjectiveTo investigate the safety and enhance skin penetration efficacy of Putocrin®, a combination containing 2% isosorbide dimethyl ether, 1% pentanediol, and 0.5% inositol.MethodsAn in vitro keratinocyte cell assay using 3‐(4,5‐dimethylthiazolyl‐2)‐2,5 diphenyltetrazolium bromide (MTT), and an in vitro EpiKutis® skin study adopted hematoxylin and eosin staining, immunostaining, and liquid chromatography–mass spectrometry (LC–MS) analysis were carried out to investigate the safety of Putocrin®. A pigskin‐Franz cell system experiment applied high‐performance liquid chromatography (HPLC) to compare the skin penetration efficiency of fluorescein isothiocyanate (Fitc)‐labeled tranexamic acid with or without the assistance of Putocrin®. The safety and efficacy of Putocrin® was further evaluated on zebrafish embryos.ResultsThe MTT assay showed that Putocrin® at concentration ≤2.5% did not significantly affect cell viability. The in vitro EpiKutis® skin study revealed that 2.5% Putocrin® did not affect skin morphology, filaggrin content, ceramide/protein, or fatty acid/protein ratios, but significantly increased loricrin content by 86.00% (p < 0.001). The pigskin‐Franz cell penetration experiment demonstrated that Fitc‐labeled tranexamic acid could barely penetrate the skin (with penetration rate of 1.121%), while Putocrin® significantly enhanced the penetration rate up to 83.983%, which was close to unlabeled tranexamic acid (90.013%). The zebrafish embryo study showed that 2.5% Putocrin® did not exert observable toxicity and obviously assisted the skin penetration of Fitc‐labeled tranexamic acid into fish embryos. These results indicate the strong enhancing skin penetration potency of Putocrin®.ConclusionThis study demonstrated the safety as well as the strong enhancing skin penetration potency of Putocrin® for cosmetics formulation use.

2024-08-01·Clinical Case Reports

Axillary and subclavian venous spasm during pacemaker implantation – A case report and literature review

Article

作者: Müssigbrodt, Andreas ; Cenac, Kurlene ; Vergier, Romain ; Inamo, Jocelyn ; Venet, Amelie

Key Clinical MessageVenous spasm is an important reason for complicated or failed implantations of cardiac implantable electronic devices. Prevention or risk reduction of venous spasm during cardiac implantable electronic device implantation may be achieved by ultrasound or fluoroscopic imaging prior to puncture, cephalic vein cut‐down, sufficient pre‐ and perioperative hydration, nitroglycerin injection and effective sedation, and analgesia.AbstractThis case report with literature review focuses on venous spasm as a potential cause for complicated implantations of cardiac implantable electronic devices. The case report is clinically relevant as it describes a progressive spasm affecting the axillary and the subclavian vein. A 66‐year‐old female complained of symptomatic atrial fibrillation (AF) and atypical atrial flutter despite interventional and medical treatment. As an ultimate treatment, she was scheduled for pacemaker implantation and atrioventricular node ablation. Several puncture attempts of the axillary vein failed. Despite venous blood aspiration, no guidewires could be advanced into the axillary vein. We performed a first venogram revealing significant spasm of the axillary vein. Another failed venous puncture occurred after change of access site to the subclavian vein. A second venogram displayed progression of the spasm, now affecting both the axillary and the subclavian veins. Normal saline perfusion was administered as well as intravenous isosorbide. Unfortunately, a repeated venogram after 15 min waiting time showed persistence of the spasm, still affecting both veins. The procedure was discontinued as the patient became uncomfortable. Venous spasm is an important reason for complicated or failed implantations of cardiac implantable electronic devices. Commonly used medical prevention and treatment are intravenous fluids and nitroglycerin. Prevention or risk reduction of venous spasm during cardiac implantable electronic device implantation may be achieved by ultrasound or fluoroscopic imaging prior to puncture, cephalic vein cut‐down, sufficient pre‐ and perioperative hydration, nitroglycerin injection and effective sedation and analgesia.

2024-03-01·American Journal of Obstetrics and Gynecology

Methods for the induction of labor: efficacy and safety

Review

作者: Sanchez-Ramos, Luis ; Levine, Lisa D ; Mozurkewich, Ellen L ; Kaunitz, Andrew M ; Sciscione, Anthony C ; Ramsey, Patrick S ; McKinney, Jordan A ; Adair, Charles David

This review assessed the efficacy and safety of pharmacologic agents (prostaglandins, oxytocin, mifepristone, hyaluronidase, and nitric oxide donors) and mechanical methods (single- and double-balloon catheters, laminaria, membrane stripping, and amniotomy) and those generally considered under the rubric of complementary medicine (castor oil, nipple stimulation, sexual intercourse, herbal medicine, and acupuncture). A substantial body of published reports, including 2 large network meta-analyses, support the safety and efficacy of misoprostol (PGE1) when used for cervical ripening and labor induction. Misoprostol administered vaginally at doses of 50 μg has the highest probability of achieving vaginal delivery within 24 hours. Regardless of dosing, route, and schedule of administration, when used for cervical ripening and labor induction, prostaglandin E2 seems to have similar efficacy in decreasing cesarean delivery rates. Globally, although oxytocin represents the most widely used pharmacologic agent for labor induction, its effectiveness is highly dependent on parity and cervical status. Oxytocin is more effective than expectant management in inducing labor, and the efficacy of oxytocin is enhanced when combined with amniotomy. However, prostaglandins administered vaginally or intracervically are more effective in inducing labor than oxytocin. A single 200-mg oral tablet of mifepristone seems to represent the lowest effective dose for cervical ripening. The bulk of the literature assessing relaxin suggests this agent has limited benefit when used for this indication. Although intracervical injection of hyaluronidase may cause cervical ripening, the need for intracervical administration has limited the use of this agent. Concerning the vaginal administration of nitric oxide donors, including isosorbide mononitrate, isosorbide, nitroglycerin, and sodium nitroprusside, the higher incidence of side effects with these agents has limited their use. A synthetic hygroscopic cervical dilator has been found to be effective for preinduction cervical ripening. Although a pharmacologic agent may be administered after the use of the synthetic hygroscopic dilator, in an attempt to reduce the interval to vaginal delivery, concomitant use of mechanical and pharmacologic methods is being explored. Combining the use of a single-balloon catheter with dinoprostone, misoprostol, or oxytocin enhances the efficacy of these pharmacologic agents in cervical ripening and labor induction. The efficacy of single- and double-balloon catheters in cervical ripening and labor induction seems similar. To date, the combination of misoprostol with an intracervical catheter seems to be the best approach when balancing delivery times with safety. Although complementary methods are occasionally used by patients, given the lack of data documenting their efficacy and safety, these methods are rarely used in hospital settings.

项与异山梨醇相关的新闻（医药）

2023-12-20

·美通社

三养Innochem,白色生物材料"异山梨醇"获得国际环保认证 ISCC Plus

通过对原料采购到销售的全过程进行评价 , 以高信赖度的国际认证为支撑，打造进军全球市场的桥头堡。异山梨醇，是由玉米等从植物资源制成的 100%生物质材料。其优异的耐久性、耐热性、耐化学性等特性扩大了其在各个领域的应用范围。韩国首尔 2023年12月20日 /美通社/ -- 三养Innochem自主研发的白色生物材料"异山梨醇（Isosorbide ) " 荣获国际环保认证，正式登入全球市场。三养集团旗下的化学子公司，三养Innochem（首席执行官：姜镐星）在首尔钟路区三养集团总部，与ISCC (International Sustainability & Carbon Certification)全球代理公司Control Union举行了异山梨醇的 'ISCC Plus' 认证书授予仪式。 ISCC Plus是赋予符合欧盟(EU)可再生能源指南 (RED, Renewable Energy Directives)的可持续性及低碳产品的国际认证制度。该认证制度涵盖从原料采购到生产和销售的供应链全过程，对产品进行了严格评估并予以认证。三养Innochem此次获得认证的异山梨醇是将从玉米等植物资源中提取的淀粉进行化学加工制成的100%生物质基础的环保材料。代替现有的石油化学材料, 用于塑料、涂料等生产, 国内只有三养Innochem在生产。利用异山梨醇制造的塑料、丙烯酸酯、粘合剂等不仅有助于减少碳排放，而且在透明度、耐久性、耐热性、耐化学性、粘合力等方面也表现突出。这些特性使其广泛应用于电子产品、汽车内外装材料、食品容器和建筑材料等领域。三养Innochem的首席执行官姜镐星表示："通过此次ISCC Plus认证，为异山梨醇进军全球奠定了基础。这将加速异山梨醇在全球市场的拓展速度，并适用于多种产品，持续扩大环保特别材料事业。" 三养集团正在积极开发基于异山梨醇特性和材料卓越性的产品。去年，三养成功研发了电动汽车用环保粘合剂并已开始批量生产。同时，还研发了利用异山梨醇的光透改善剂来提高日间行车灯的光透率，并降低黄色度的高透射聚碳酸酯材料。此外，三养还致力于开发电动汽车电池的热管理材料等，正在逐步扩大其应用领域。

带量采购医药出海一致性评价

2023-12-13

·PRNewswire

Sytheon Granted 2 New US Patents on Isosorbide Diesters for Treating Atopic Dermatitis, Seeking Exclusive Partner to Bring to Market

PARSIPPANY, N.J., Dec. 13, 2023 /PRNewswire/ -- Sytheon is thrilled to announce that its new turnkey product for treating Atopic Dermatitis (eczema) has further patent protection – and is actively seeking an exclusive partner to bring it to the OTC dermatological market. There is currently an unmet need for a sustainable, safe, and cost-effective product for those with mild to moderate Atopic Dermatitis (AD). Sytheon has a turnkey product, ActSES®, with solid science, patent protection, and clinical validation by UC-Davis, CA dermatologists – and a new clinical study on children underway. Continue Reading Sytheon is thrilled to announce that its new turnkey product for treating eczema has further patent protection. Post this Sytheon is seeking an exclusive partnership to bring turnkey atopic dermatitis treatment product to market. Market Opportunity for Atopic Dermatitis (AD) Topical therapies are a mainstay treatment for AD, particularly for children or those with mild-to-moderate disease who may not qualify for systemic medications. The complexity of chronic AD is increased by the interplay of skin barrier dysfunction and immune dysregulation, resulting in the perpetuation of AD signs and symptoms. ActSES®, a unique synergistic combination product of Isosorbide di-(linoleate/oleate) (Hydra Synol® IDL) + Isosorbide di-caprylate (Hydra Synol® DOI), has been developed by Sytheon to serve this unmet need. The effects of topically applied ActSES® are not limited to barrier repair but synergistically inhibit inflammatory cascades that amplify pruritus and cutaneous eruption. For ActSES®, Sytheon has obtained two new US patents 11,753,414 (method) & 11,753,415 (composition), entitled "Composition and Methods for Treating Atopic Dermatitis." Sytheon has two earlier US Patents (10,597,402 & 11,312,725), which disclose "compositions and methods for restoring epidermal integrity and function and treating dermatological diseases." Sytheon is actively looking for an exclusive partnership with the right organization to bring this turnkey product to the OTC dermatological market. To inquire, please send us a message here. This news piece is also featured on SpecialChem and HAPPI. About Sytheon Sytheon is an innovative research-focused company committed to developing high-performance active ingredients for the personal care industry. Inspired by nature, all of Sytheon's ingredients have been scientifically and clinically validated to improve the health and beauty of the skin. Visit our website: SOURCE Sytheon Ltd.

2023-12-11

·信狐药迅

京新 1类新药安达西尼获批文，默克特泊替尼获批进口 | 新获批（12.4-12.10）

每周药品注册受理数据，分门别类呈现，一目了然。（12.4-12.10）新药上市申请药品名称企业名称分类受理号妥拉美替尼胶囊上海科州药物研发有限公司1CXHS2300030妥拉美替尼胶囊上海科州药物研发有限公司1CXHS2300031安达西尼胶囊浙江京新药业股份有限公司1CXHS2200018甘精胰岛素注射液辽宁博鳌生物制药有限公司15CXSS1900028舒格利单抗注射液辉瑞投资有限公司2.2CXSS2300016新药临床申请药品名称企业名称分类受理号177Lu-LNC1004烟台蓝纳成生物技术有限公司1CXHL2301027SHR2554片江苏恒瑞医药股份有限公司1CXHL2301008司美格鲁肽注射液深圳翰宇药业股份有限公司2.2CXHL2300983司美格鲁肽注射液深圳翰宇药业股份有限公司2.2CXHL2300984注射用THDBH120东宝紫星(杭州)生物医药有限公司1CXHL2301038注射用THDBH120东宝紫星(杭州)生物医药有限公司1CXHL2301039注射用THDBH120东宝紫星(杭州)生物医药有限公司1CXHL2301040西罗莫司口服溶液杭州中美华东制药有限公司2.4CXHL2300967AK2017注射液安徽安科生物工程(集团)股份有限公司1CXSL2300619C-13-60细胞制剂重庆精准生物技术有限公司1CXSL2300624CAB-AXL-ADC注射剂凯博斯(上海)生物医药有限公司1CXSL2300662MC-1-50细胞制剂重庆精准生物技术有限公司1CXSL2300620REV001注射液上海行深生物科技有限公司1CXSL2300606WST04胶囊上海上药信谊药厂有限公司1CXSL2300644重组抗 Claudin18.2 全人源单克隆抗体注射液华兰基因工程(河南)有限公司1CXSL2300651冻干人用狂犬病疫苗(人二倍体细胞)长春百克生物科技股份公司2.5CXSL2300615仿制药申请药品名称企业名称分类受理号丙戊酸钠口服溶液北京民康百草医药科技有限公司4CYHS2200994他达拉非片山东新时代药业有限公司4CYHS2200404他达拉非片山东新时代药业有限公司4CYHS2200405他达拉非片山东新时代药业有限公司4CYHS2200406他达拉非片山东新时代药业有限公司4CYHS2200407他达拉非片卓和药业集团股份有限公司4CYHS2200243他达拉非片卓和药业集团股份有限公司4CYHS2200244他达拉非片烟台市东盛生物科技有限公司4CYHS2200084利那洛肽胶囊双鹤药业(海南)有限责任公司4CYHS2201778卡前列素氨丁三醇注射液广州瑞尔医药科技有限公司4CYHS2201171右酮洛芬氨丁三醇注射液中润药业有限公司3CYHL2300118吡非尼酮片山东华铂凯盛生物科技有限公司3CYHS2300947哌柏西利胶囊河北泽运生物医药科技有限公司4CYHS2200817哌柏西利胶囊正大天晴药业集团股份有限公司4CYHS2200590哌柏西利胶囊正大天晴药业集团股份有限公司4CYHS2200591哌柏西利胶囊正大天晴药业集团股份有限公司4CYHS2200592奥美沙坦酯氨氯地平片浙江诺得药业有限公司4CYHS2201502孟鲁司特钠咀嚼片国药集团致君(深圳)坪山制药有限公司4CYHS2201305富马酸丙酚替诺福韦片海南中和药业股份有限公司4CYHS2200726左乙拉西坦片天地恒一制药股份有限公司4CYHS2200920左乙拉西坦片天地恒一制药股份有限公司4CYHS2200921左氧氟沙星片四川信拓医药技术有限公司4CYHS2200474平衡盐冲洗液华仁药业股份有限公司3CYHS1700016异山梨醇口服溶液鲁南贝特制药有限公司3CYHL2300116恩替卡韦片湖南迪诺制药股份有限公司4CYHS2200140恩格列净二甲双胍缓释片乐普药业股份有限公司3CYHS2300065枸橼酸坦度螺酮片重庆圣华曦药业股份有限公司4CYHS2201164氢溴酸伏硫西汀片山东京卫制药有限公司4CYHS2202032玻璃酸钠滴眼液苏州弘森药业股份有限公司4CYHS2300084玻璃酸钠滴眼液苏州弘森药业股份有限公司4CYHS2300085琥珀酸地文拉法辛缓释片石药集团欧意药业有限公司3CYHS2202106瑞舒伐他汀钙片苏州东瑞制药有限公司4CYHS2200803甲磺酸仑伐替尼胶囊山东新时代药业有限公司4CYHS2200833甲钴胺片北京民康百草医药科技有限公司4CYHS2101976盐酸左西替利嗪口服溶液福安药业集团湖北人民制药有限公司3CYHS2102212盐酸左西替利嗪口服滴剂万特制药(海南)有限公司4CYHS2201845盐酸托莫西汀胶囊山东达因海洋生物制药股份有限公司4CYHS2200662硝苯地平控释片广州玻思韬控释药业有限公司4CYHS2200886硝苯地平控释片南京星银药业集团有限公司4CYHS2200691硝苯地平控释片山西同达药业有限公司4CYHS2102217硫酸氢氯吡格雷片浙江京新药业股份有限公司4CYHS2201252硫酸氢氯吡格雷片国药集团致君(深圳)制药有限公司4CYHS2200826硫酸特布他林雾化吸入用溶液成都奥邦药业有限公司4CYHS2200172舒更葡糖钠注射液齐鲁制药(海南)有限公司4CYHS2200582舒更葡糖钠注射液齐鲁制药(海南)有限公司4CYHS2200583舒更葡糖钠注射液长沙市如虹医药科技股份有限公司4CYHS2200396舒更葡糖钠注射液长沙市如虹医药科技股份有限公司4CYHS2200397苯磺酸左氨氯地平片江苏万高药业股份有限公司4CYHS2200840草酸艾司西酞普兰片成都康弘药业集团股份有限公司4CYHS2201027草酸艾司西酞普兰片成都康弘药业集团股份有限公司4CYHS2201028达格列净片福元药业有限公司4CYHS2302511达格列净片福元药业有限公司4CYHS2302512阿哌沙班片湖南赛隆药业有限公司4CYHS2200472进口申请药品名称企业名称分类受理号CFT8919片C4 Therapeutics, Inc.1JXHL2300237CFT8919片C4 Therapeutics, Inc.1JXHL2300238吉非替尼片Natco Pharma Limited5.2JYHS2200084唑来膦酸注射液Gland Pharma Limited5.2JXHS2000009左氧氟沙星地塞米松滴眼液NTC S.r.l.5.1JXHS2200108氨吡啶缓释片Aurobindo Pharma Limited5.2JYHS2200001泊沙康唑口服混悬液Deva Holding A.S.5.2JYHS2200100泮托拉唑钠肠溶片Hetero Labs Limited5.2JYHS2200044泮托拉唑钠肠溶片Hetero Labs Limited5.2JYHS2200045瑞加诺生注射液Dr. Reddy's Laboratories Limited5.2JYHL2300001盐酸普拉克索缓释片北京金康驰医药投资有限公司5.2JXHS1900040盐酸普拉克索缓释片北京金康驰医药投资有限公司5.2JXHS1900041盐酸普拉克索缓释片北京金康驰医药投资有限公司5.2JXHS1900042盐酸普拉克索缓释片北京金康驰医药投资有限公司5.2JXHS1900043盐酸普拉克索缓释片北京金康驰医药投资有限公司5.2JXHS1900044盐酸特泊替尼片Merck (Schweiz) AG5.1JXHS2200033中药相关申请药品名称企业名称分类受理号双参苓颗粒北京盈科瑞创新药物研究有限公司1.1CXZL2300060连花清咳颗粒石家庄以岭药业股份有限公司2.2CXZL2300062注：灰色字体部分结论为不批准或收到通知件；

抗体药物偶联物申请上市疫苗临床申请

100 项与异山梨醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00347	异山梨醇	C01	DB09401

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
梅尼埃病	日本	Kowa Co., Ltd.	1988-02-22
低眼压	日本	Kowa Co., Ltd.	1968-12-12
颅内低压	日本	Kowa Co., Ltd.	1968-04-18
泌尿系疾病	日本	Kowa Co., Ltd.	1968-04-18